Related Experiment Videos

beta(3)-Adrenoceptor antagonism improves clinical outcomes of chronic heart failure

Tongguo Wu1, Lexin Wang

  • 1Department of Cardiology, The Red Cross Hospital of Guangzhou City, The Fourth Affiliated Hospital of Jinan University, Guangzhou 510220, PR China. wutongguo@sohu.com

Medical Hypotheses
|April 13, 2007
PubMed

Insights

Beta-3 adrenoceptors are overexpressed in heart failure, worsening cardiac function. Blocking these receptors may improve outcomes for chronic heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Chronic heart failure (CHF) is a major global health concern.
  • Beta-1 adrenoceptors are established targets in CHF treatment, with blockers reducing mortality.
  • Emerging evidence indicates beta-3 adrenoceptors are overexpressed in failing hearts.

Purpose of the Study:

  • To investigate the role of overexpressed beta-3 adrenoceptors in CHF pathogenesis.
  • To hypothesize that beta-3 adrenoceptor antagonism can improve cardiac function and outcomes in CHF.

Main Methods:

  • Review of recent animal and human studies on beta-3 adrenoceptor expression and function in heart failure.
  • Analysis of the impact of beta-3 adrenoceptor stimulation on ventricular function.
  • Formulation of a hypothesis based on observed over expression and functional effects.

Main Results:

  • Studies show increased expression of beta-3 adrenoceptors in the failing heart.
  • Stimulation of these overexpressed beta-3 adrenoceptors leads to decreased ventricular function.
  • This suggests a detrimental role for beta-3 adrenoceptors in CHF.

Conclusions:

  • Overactivity of beta-3 adrenoceptors is a potential critical mechanism in CHF.
  • Beta-3 adrenoceptor antagonism, as an adjunct therapy, may enhance conventional CHF treatments.
  • Targeting beta-3 adrenoceptors offers a novel therapeutic strategy for improving cardiac function and clinical outcomes in CHF patients.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...